#Netherlands #Amsterdam #Oncology Care #Ultima Genomics #Hartwig Medical

Introduction

In a significant move towards enhancing cancer diagnostics, the Hartwig Medical Foundation and Ultima Genomics have announced an expansion of their collaboration focusing on whole-genome sequencing (WGS) in oncology. This partnership marks an evolution in medical technology and aims to improve the precision and accessibility of cancer care globally.

The Evolution of Collaboration

Hartwig Medical Foundation has been at the forefront of integrating whole-genome sequencing into cancer diagnostics. Since 2024, the foundation utilized Ultima's first-generation sequencing system, the UG100®, to create innovative bioinformatics solutions and demonstrate the efficacy of advanced sequencing technologies in detecting cancer indicators. The recent agreement to adopt the UG200™ system represents a leap forward in their ongoing efforts to provide clinicians with comprehensive genomic data essential for informed treatment decisions.

The Advantages of the UG200™ System

The UG200™, Ultima’s second-generation sequencing platform, is designed to empower clinical laboratories with a range of operational benefits. The system is enhanced with Solaris 2.0 workflows, enabling straightforward integration into lab processes. The new isothermal amplification method eliminates the previously required emulsion-based amplification, significantly streamlining laboratory operations. This represents a pivotal shift towards more effective, automated, and cost-efficient cancer diagnostics.

Focus on Minimal Residual Disease Monitoring

One of the cornerstone features of this expanded collaboration is the emphasis on monitoring minimal residual disease (MRD) through Ultima's ppmSeq technology. This approach allows for the detection of cancer during its earliest stages, boosting the ability to monitor patients post-treatment effectively. With a sensitivity reaching single-digit part-per-million levels, ppmSeq positions Hartwig and Ultima as leaders in innovative cancer management solutions.

Supporting Clinical Applications

The collaboration is set to innovate beyond standard cancer diagnostics by integrating WGS into blood-based circulating tumor DNA (ctDNA) monitoring. This initiative aligns with ongoing clinical studies at the Netherlands Cancer Institute, aimed at evaluating the efficacy of ctDNA as a biomarker linked to WGS-based diagnostics. Such studies are crucial in establishing the validation pathway for broader adoption in oncology and determining the associated economic impacts.

Future Developments

In addition to developing a validated WGS-based approach for MRD monitoring, Hartwig and Ultima are poised to enhance their comprehensive open-source cancer genomics tools, such as OncoAnalyser. This improvement will ensure that genomic data remains openly accessible for clinical use, promoting the implementation of Ultima’s technology within various healthcare settings.

Conclusion

The partnership between Hartwig Medical Foundation and Ultima Genomics embodies a forward-thinking approach to cancer diagnostics. By enhancing whole-genome sequencing capabilities, the two organizations are working to ensure that personalized, data-driven approaches become standard in oncology care. This collaboration represents a pivotal moment in the quest for improved cancer treatment methodologies and patient outcomes.

About Hartwig Medical Foundation

Hartwig Medical Foundation is a nonprofit based in the Netherlands focused on revolutionizing cancer treatment through advanced genomic insights. They aim to enhance patient care by integrating software innovations, clinical analyses, and cutting-edge diagnostics.

About Ultima Genomics

Ultima Genomics is committed to acquiring deeper genomic data efficiently and cost-effectively, propelling biological research and improving healthcare outcomes. Their innovative sequencing architecture is set to drive significant advancements in genomic technology for the future.